

SWIXX AND ALK SIGN AGENCY DEAL FOR WEST BALKANS

SWIXX ANNOUNCEMENT NO. 28

February 17th, 2020

Baar, Switzerland – Swixx BioPharma AG announced today the signing of a Distribution and Promotion Agreement with ALK Slovakia s. r. o., a subsidiary of ALK-Abelló A/S of Horsholm, Denmark (ALK). The contract gives Swixx the right to commercialize (market, sell and distribute) ALK’s novel Allergy Immunotherapy (AIT) portfolio, including both the allergy medicines ACARIZAX®, Alutard SQ®, GRAZAX®, ITULAZAX®, and RAGWIZAX®, and also the emergency medicine Jext® in the Western Balkan countries of Croatia, Serbia and Slovenia.

“This contract with ALK for its exciting portfolio takes Swixx into a new therapeutic area of allergology,” observed Swixx CEO, Jean-Michel Lespinasse. “ALK offers novel, evidence-based medicines that represent causal treatment of allergy and gradually build up tolerance to allergens and also offers innovative, emergency antidotes for allergic reactions. We feel privileged to represent such a science-based company and to help bring these innovative therapies to patients.”

Swixx’s COO, Dr. Dezso, Martha a that enthused that he ALK contract “represents a great opportunity for Swixx to work with a uniquely broad portfolio of biologics. With ALK, Swixx can offer a complete solution for common respiratory ailments such as house dust mite, grass, trees from the birch tree family and ragweed. There is a great unmet need for new treatments in this area, and we look forward to bring these solutions to healthcare professionals, patients and their families.”

About Swixx BioPharma AG

Swixx now operates fully-owned subsidiaries across Central and Eastern Europe, offering coverage from Moscow to Prague and from Tallinn to Sofia. With 350 employees and over 150M Euros in sales, Swixx is now the largest and fastest-growing dedicated agent for biopharma in CEE. The company has gathered outstanding specialty pharmaceutical, rare disease, medical device and OTC / consumer healthcare talent under one roof. For more info about Swixx, please visit: www.swixxbiopharma.com

About ALK

ALK is a global allergy solutions company, offering a wide range of allergy treatments, products and services that meet the unique needs of allergy sufferers, their families and healthcare professionals. ALK has approximately 2,400 employees, with subsidiaries, production facilities and distributors worldwide. For more information about ALK, please visit: www.alk.net

Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321

Note on Unsubscribing from Swixx Announcement Mailing List: In accordance with the GDPR (General Data Protection Regulation) provisos of the EU, should you wish to unsubscribe / opt out of our mailing list, please send to Maja.Boskovic@swixxbiopharma.com a one-line message „Please unsubscribe me.“